HUP0401351A2 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor - Google Patents

Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor

Info

Publication number
HUP0401351A2
HUP0401351A2 HU0401351A HUP0401351A HUP0401351A2 HU P0401351 A2 HUP0401351 A2 HU P0401351A2 HU 0401351 A HU0401351 A HU 0401351A HU P0401351 A HUP0401351 A HU P0401351A HU P0401351 A2 HUP0401351 A2 HU P0401351A2
Authority
HU
Hungary
Prior art keywords
short
chain
group
general formula
recurrence
Prior art date
Application number
HU0401351A
Other languages
Hungarian (hu)
Inventor
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Original Assignee
Tanabe Seiyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co., Ltd. filed Critical Tanabe Seiyaku Co., Ltd.
Publication of HUP0401351A2 publication Critical patent/HUP0401351A2/en
Publication of HUP0401351A3 publication Critical patent/HUP0401351A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

A találmány poliszacharid-konjugátumot tartalmazó, rosszindulatútumorok metasztázisát gátló vagy kiújulását megelőző gyógyászatikészítményekre vonatkozik. Közelebbről a találmány olyan,rosszindulatú tumor metasztázisát gátló vagy kiújulását megelőzőgyógyászati készítményekre vonatkozik, amelyek hatóanyagként olyanpoliszacharid-származékot vagy ennek sóját tartalmazzák, amelyben egy,tumor elleni hatású hatóanyaghoz, így például a következőkbenismertetésre kerülő (I) vagy (II) általános képletűkamptotecinszármazékhoz egy aminosavon vagy 2-8 aminosavból - ezeklehetnek azonosak vagy eltérőek - álló peptiden át karboxilcsoportottartalmazó poliszacharid kapcsolódik. Az (I) általános képletben R1jelentése helyettesített vagy helyettesítetlen rövid szénláncúalkilcsoport, Xl jelentése -NHR2 általános képletű csoport (ebben aképletben R2 jelentése hidrogénatom vagy rövid szénláncú alkilcsoport)és Alk jelentése egyenes láncú vagy elágazó láncú, a láncban adottesetben oxigénatomot tartalmazó 1-6 szénatomos alkiléncsoport és a(II) általános képletben R2-R6 közül kettő egymással szomszédoscsoport rövid szénláncú alkiléncsoportot alkot, és az említett rövidszénláncú alkiléncsoport szénatomjai közül az egyik aminocsoporttalszubsztituált, míg R2-R6 közül a többi három helyettesítő hidrogén-vagy halogénatomot vagy rövid szénláncú alkilcsoportot jelent. ÓThe invention relates to medicinal preparations containing a polysaccharide conjugate that inhibit the metastasis of malignant tumors or prevent their recurrence. More specifically, the invention relates to medicinal preparations that inhibit the metastasis of a malignant tumor or prevent its recurrence, which contain as an active ingredient a polysaccharide derivative or a salt thereof, in which an active ingredient with an anti-tumor effect, such as, for example, the camptothecin derivative of the general formula (I) or (II) introduced below, is on an amino acid or A polysaccharide containing a carboxyl group is connected through a peptide consisting of 2-8 amino acids - these can be the same or different. In the general formula (I), R1 means a substituted or unsubstituted short-chain alkyl group, Xl means a group of the general formula -NHR2 (in this formula, R2 means a hydrogen atom or a short-carbon chain alkyl group) and Alk means a straight-chain or branched-chain alkylene group with 1-6 carbon atoms, possibly containing an oxygen atom in the chain and in the general formula (II), two adjacent groups of R2-R6 form a short-chain alkylene group, and one of the carbon atoms of the mentioned short-chain alkylene group is sub-substituted by an amino group, while the other three of R2-R6 represent hydrogen or halogen atoms or short-chain alkyl groups. HE

HU0401351A 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor HUP0401351A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor

Publications (2)

Publication Number Publication Date
HUP0401351A2 true HUP0401351A2 (en) 2004-12-28
HUP0401351A3 HUP0401351A3 (en) 2011-02-28

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401351A HUP0401351A3 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor

Country Status (18)

Country Link
EP (1) EP1418947A1 (en)
KR (1) KR20040027972A (en)
CN (1) CN100372570C (en)
AR (1) AR035137A1 (en)
AU (1) AU2002328093B2 (en)
BR (1) BR0212036A (en)
CA (1) CA2457056C (en)
HU (1) HUP0401351A3 (en)
IL (1) IL160148A0 (en)
MX (1) MXPA04001599A (en)
NO (1) NO20041194L (en)
NZ (1) NZ530947A (en)
PL (1) PL368319A1 (en)
RU (1) RU2275913C2 (en)
TW (1) TWI313609B (en)
UA (1) UA75450C2 (en)
WO (1) WO2003015826A1 (en)
ZA (1) ZA200400917B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (en) 2007-03-29 2009-07-03 Proteins & Peptides Man DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS
EP3693454A1 (en) 2008-07-16 2020-08-12 Children's Medical Center Corporation Organ mimic device with microchannels and methods of use and manufacturing thereof
AU2012262139B2 (en) * 2011-06-02 2017-02-23 Children's Medical Center Corporation Methods and uses for ex vivo tissue culture systems
PL221351B1 (en) 2012-03-14 2016-03-31 Politechnika Warszawska Method for obtaining polysaccharide nanoparticles
KR102087017B1 (en) 2012-10-11 2020-03-10 다이이찌 산쿄 가부시키가이샤 Antibody-drug conjugate
EP2910573B1 (en) * 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI718144B (en) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BR112017027690A2 (en) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “method for producing an antibody-drug conjugate composition, and antibody-drug conjugate composition
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (en) 2017-01-17 2020-04-15 第一三共株式会社 Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
TW202330036A (en) 2017-05-15 2023-08-01 日商第一三共股份有限公司 Manufacturing method of antibody-drug conjugates
CN117838880A (en) 2017-08-31 2024-04-09 第一三共株式会社 New method for preparing antibody-drug conjugate
EP3677589A4 (en) 2017-08-31 2021-04-21 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
CN117815404A (en) 2018-05-18 2024-04-05 第一三共株式会社 anti-MUC 1 antibody-drug conjugates
CN109481691A (en) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0640622T3 (en) * 1993-02-26 2000-10-23 Drug Delivery System Inst Ltd Polysaccharide derivative and drug carrier
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
WO1997038727A1 (en) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Medicament composite
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (en) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 Low contract photo-solidification cladding material, its prepn. method and use
EA003398B1 (en) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Drug complex with polymeric carrier

Also Published As

Publication number Publication date
CA2457056A1 (en) 2003-02-27
ZA200400917B (en) 2004-08-25
RU2004108141A (en) 2005-04-20
AU2002328093B2 (en) 2005-05-05
IL160148A0 (en) 2004-07-25
CN1545423A (en) 2004-11-10
PL368319A1 (en) 2005-03-21
KR20040027972A (en) 2004-04-01
NO20041194L (en) 2004-03-19
CA2457056C (en) 2008-07-22
TWI313609B (en) 2009-08-21
NZ530947A (en) 2006-04-28
BR0212036A (en) 2004-08-17
CN100372570C (en) 2008-03-05
MXPA04001599A (en) 2004-07-08
UA75450C2 (en) 2006-04-17
EP1418947A1 (en) 2004-05-19
AR035137A1 (en) 2004-04-14
WO2003015826A1 (en) 2003-02-27
RU2275913C2 (en) 2006-05-10
HUP0401351A3 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
HUP0401351A2 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor
HUP0105231A2 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents and medicaments containing the compounds
GB2424882A (en) Selective kinase inhibitors
TR200103186T2 (en) Quinoline derivatives as inhibitors of MEK enzymes
GB0114286D0 (en) Nucleoside Derivatives
HUP0002454A2 (en) Targeted therapeutic delivery of vitamin d compounds
HUP0100156A2 (en) Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
RU94042922A (en) Novel compounds, method for their production, pharmaceutical composition
GR3037076T3 (en) Camptothecin derivatives
HUP0101146A2 (en) Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
AR003936A1 (en) TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT USEFUL TO INHIBIT ABNORMAL GROWTH OF CELLS.
TR200200717T2 (en) Therapeutic quinazoline derivatives.
AR018175A1 (en) COMPOUNDS OF INDOL-3-GLIOXYLAMIDES REPLACED, USEFUL AS ANTITUMURAL MEDICINES, PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH DERIVATIVES, USE OF SUCH DERIVATIVES FOR THE PREPARATION OF ANTITUMORAL MEDICINES AND PREPARED MEDICINES.
CA2188043A1 (en) 7,11 disubstituted camptothecin derivatives, formulations containing such derivatives and their use
HUP0204167A2 (en) Clorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
TR200401793T4 (en) Perindopril salt and pharmaceutical compositions containing it.
HUP0203184A2 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
TR199900336T2 (en) Tetrahydroquinoline derivatives as EAA antagonists.
TW201427693A (en) High molecular compound combining camptothecin and antitumor effect potentiator and use thereof
HUP0203524A2 (en) 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity, their use and pharmaceutical compositions containing them
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
IL151198A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
HUP9700810A2 (en) Acids and esters of diosmetin and pharmaceutical compositions containing them
IL111725A0 (en) 3'-aziridino-anthracycline derivatives, their preparation and pharmaceutical compositions containing them
TR200103151T2 (en) A pharmaceutical formulation containing a carboxypeptidase U inhibitor and a thrombin inhibitor.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

Free format text: FORMER OWNER(S): TANABE SEIYAKU CO., LTD., JP

FD9A Lapse of provisional protection due to non-payment of fees